Fetal toxicity of valsartan and possible reversible adverse side effects

✍ Scribed by Nadia Berkane; Patrick Carlier; Lieve Verstraete; Emmanuelle Mathieu; Nazbanou Heim; Serge Uzan

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 60 KB
• Volume: 70
• Category: Article
• ISSN: 1542-0752
• DOI: 10.1002/bdra.20047

✦ Synopsis

Abstract

BACKGROUND

Published cases suggest that the use of angiotensin II receptor antagonists is fetotoxic during the third trimester, but not in early pregnancy. CASE: We report a case in which the adverse fetal effect of angiotensin II receptor antagonist treatment was reversed. A woman with chronic hypertension was treated with valsartan until gestation week (GW) 20, when a complete anhydramnios was observed. Six days after interruption of the treatment, amniotic fluid reappeared. It reached a normal level at GW 23.5. The plasmatic creatinine level and the renal ultrasound examination were within normal limits at the six‐month follow‐up.

CONCLUSIONS

Whereas angiotensin‐II‐receptor antagonist generates a severe renal toxicity, this case suggests that, at least in the first half of pregnancy, these effects can be reversed. Birth Defects Research (Part A) 67:, 2004. © 2004 Wiley‐Liss, Inc.